Re: New research report 5/11/16 by Marcel Wijma, Van Leeuwenhoeck Institute
|
5
|
Resverlogix Corp.
|
May 12, 2016 12:02PM
|
Re: Total Patient Hours Question
|
5
|
Resverlogix Corp.
|
Sep 17, 2019 09:18PM
|
Re: 3 Weeks To The 31st
|
5
|
Zenith Epigenetics
|
Mar 10, 2017 11:22AM
|
Re: Bioasis Announces Investor Relations Service Agreement with Stern IR
|
5
|
BIOASIS TECHNOLOGIES INC
|
Oct 05, 2018 10:33AM
|
Re: RVX 2019_11_18 Webcast - Detailed Preliminary Results of BETonMACE - Transcript
|
5
|
Resverlogix Corp.
|
Nov 19, 2019 08:18AM
|
Re: No mention of efficacy again...
|
5
|
Resverlogix Corp.
|
Mar 29, 2019 03:41PM
|
Re: Third Eye, AHA, US Listing
|
5
|
Resverlogix Corp.
|
Sep 11, 2019 03:41PM
|
Re: Properly powered? What does the FDA think?
|
5
|
Resverlogix Corp.
|
May 11, 2018 09:52AM
|
Re: Modulating ZEN‐3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform
|
5
|
Zenith Epigenetics
|
Sep 02, 2018 12:27PM
|
Re: RRR %
|
5
|
Resverlogix Corp.
|
Jul 01, 2019 10:19AM
|
Re: Apabetalone MOA diagram
|
5
|
Resverlogix Corp.
|
Sep 28, 2019 10:16PM
|
Two more clinical study sites added to the ZEN-3694/enzalutamid... mCRPC trial
|
5
|
Zenith Epigenetics
|
Sep 02, 2018 12:42PM
|
Re: When in Rome.......ESC presentations from August now online
|
5
|
Resverlogix Corp.
|
Sep 25, 2016 11:07PM
|
Re: RVX, protein, inflammation and MS
|
5
|
Resverlogix Corp.
|
Mar 27, 2017 02:01PM
|
Re: Not even on the radar in this "state of the art" review
|
5
|
Resverlogix Corp.
|
Jun 20, 2018 03:07PM
|
Re: Enzalutamide effective in non-metastatic prostate cancer
|
5
|
Zenith Epigenetics
|
Jun 29, 2018 10:51AM
|
Re: Compounds and Autoimmune
|
5
|
Zenith Epigenetics
|
Jun 21, 2016 04:42PM
|
Re: ESC Wrap Up for Sunday Sept 1....
|
5
|
Resverlogix Corp.
|
Sep 02, 2019 03:47PM
|
News at BIO International next week?
|
5
|
Resverlogix Corp.
|
Jun 01, 2018 12:01PM
|
BET inhibitors promising therapy for rare pediatric brain tumor
|
5
|
Zenith Epigenetics
|
Feb 28, 2017 12:40PM
|